Surrozen, Inc./DE
Current- Director 2021 to present
Executive record
Alpha ID: alpha:person:christopher-y-chaiVersion: public-0As of: 2026-10-01
Connect capital, control, accountability, and evidence.
Mr. Chai has served as a venture partner at SR One Capital Management since 2021, advising portfolio companies on Wall Street engagement and financing strategy. He previously served as CFO of Principia Biopharma from 2013 to 2020, leading the company from early-stage to acquisition by Sanofi. He also held CFO roles at MAP Pharmaceuticals and CV Therapeutics.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageNo published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageAlpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
sec filing · Source published: Apr 1, 2026 · Retrieved: May 16, 2026
sec proxy · Source published: Apr 1, 2026 · Retrieved: Apr 25, 2026
public source · Source published: Date unavailable · Retrieved: Date unavailable
No published record changes are available in this projection.
Identity
unclaimed
Evidence
source reported
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-01